Stimulation via TLR4/MD-2 to reverse Type 1 diabetes
US10457738B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 22, 2018 |
| Grant date | Oct 29, 2019 |
| Priority date | — |
| Expiry date | Feb 22, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods and compositions for treating Type I diabetes in a subject. Agents selected from a TLR4 agonist, a TLR4/MD-2 agonist, or a combination thereof may be used in the disclosed methods and compositions. Also disclosed are methods of restoring adaptive immune T cell tolerance, treating pernicious insulitis, improving immune tolerance, and treating autoimmune diseases using the disclosed methods and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.